Stocks-EBS-Emergent BioSolutions Inc

EBS Emergent BioSolutions Inc

14.55 0.90 (6.59%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Stocks-EBS-Emergent BioSolutions Inc
EBS Emergent BioSolutions Inc
Invest
0% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
725.87M
Day’s Range
13.79
-
14.84
52W Range
10.59
-
47.50
Volume (3M)
1.01M
Price-Earnings Ratio
18.63
Revenue
1.51B

Emergent BioSolutions Inc Latest News

View All
Emergent BioSolutions Inc. (NYSE: EBS): Can The Stock Still Lose Despite An 18.04% YTD Gain?Emergent BioSolutions Inc. (NYSE: EBS): Can The Stock Still Lose Despite An 18.04% YTD Gain?Marketing Sentinel20 days agoThe Emergent BioSolutions Inc. (EBS) had a good session last reading, didn’t it?The Emergent BioSolutions Inc. (EBS) had a good session last reading, didn’t it?US Post News23 days agoEmergent BioSolutions to cut 5% of its workforce in reorganization effortEmergent BioSolutions to cut 5% of its workforce in reorganization effortMarketWatch25 days ago
Pinned Post
eToro Team
eToro
10 days ago
🎉 Here’s a little preview introducing 16 YEARS of INVESTING on eToro 😏🤑 With love, - The eToro Team youtu.be/UFYvpJxh2qA
How can eToro celebrate 16 years of Investing?
youtu.be
Celebrating 16 years of investing together 💚 #etoro16
Like CommentShare
Show more comments2 of 57
1 reply
null
.
Top Discussions

About Emergent BioSolutions Inc

Emergent BioSolutions is a biopharmaceutical organisation specialising in the development and manufacture of antibody therapeutics, such as vaccines and biodefence equipment. Founded in 1998, this multinational organisation is based in Gaithersburg, Maryland, USA. Although the highest concentration of company operations is based in the United States, Emergent BioSolutions has manufacturing, administrative, and development facilities all over the globe, including Canada, Portugal, and Singapore. As a leader in the development and manufacture of immunobiotics and biodefence therapeutics, Emergent BioSolutions collaborates with the broader industry, governments, and healthcare sectors. In June 2020, Emergent BioSolutions signed a five-year contract with Janssen Pharmaceuticals, Inc. part of Johnson and Johnson for the manufacture and rollout of a Covid-19 vaccine. This deal was reported to be worth $480m over 2 years. The company manufactures medicines for infectious diseases like cholera and typhoid, and Narcan for the emergency treatment of opioid overdoses. In addition, the company produces the only anthrax vaccine licensed by the U.S. Food and Drug Administration. With revenue exceeding $1.5bn in 2020, this organisation’s competitors in the industry include Novavax, Moderna, and Inovio. Emergent BioSolutions trades on the NYSE under the ticker EBS. Monitor the EBS share price by adding it to your eToro watchlist.
2.4K
Employees
Gaithersburg, Maryland, US
HQ
1998
Founded
Robert G. Kramer, Sr., MBA
CEO
Show More
Med TechNYSE

Upcoming Earnings

23
FEB
REPORTS
Emergent BioSolutions Inc Q4 2022 earnings report is expected to be released after market open

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
42
Very Low
Industry 
Avg. 47 
44
Environment
52
Social
33
Governance

People Also Bought